8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K



                                 CURRENT REPORT

                         Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported): June 25, 2004



                           Integrated BioPharma, Inc.
                           --------------------------
             (Exact name of registrant as specified in its charter)


          Delaware                       000-28876                22-2407475
          --------                       ---------                ----------
 (State or other jurisdiction of   (Commission File Number)      (IRS Employer
 incorporation or organization)                              Identification No.)


           225 Long Avenue
        Hillside, New Jersey                          07205
        --------------------                          -----
(Address of principal executive offices)            (Zip Code)


       Registrant's telephone number, including area code: (973) 926-0816



                                 Not Applicable
          (Former name or former address, if changed since last report)






Item 5.       Other Events and Regulation FD Disclosure.

         On June 25, 2004, Integrated BioPharma, Inc., a Delaware corporation
(the "Company"), issued a press release announcing its discovery that its common
stock had been listed without its knowledge, consent or authority on a German
stock exchange. The press release is attached as an exhibit to this Report.


Item 7.      Financial Statements and Exhibits

(c) Exhibits.

Exhibit No.  Description

99.1         Press Release issued by Integrated BioPharma, Inc. on June 25, 2004






                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


Date:  June 28, 2004            INTEGRATED BIOPHARMA, INC.


                                By: /s/ Eric Friedman
                                Eric Friedman
                                Vice President and Chief Financial Officer






Exhibit Index


Exhibit No.  Description

99.1         Press Release issued by Integrated BioPharma, Inc. on June 25, 2004

EX-99

                                                                    EXHIBIT 99.1

FOR IMMEDIATE RELEASE                                Contact: Jamie E. Levey
June 25, 2004                                        Investor Relations
                                                     (888) 319-6962


                 Integrated BioPharma Seeks Immediate Delisting
                     and Halt of Trading on Berlin Exchange


HILLSIDE, N.J., June 25, 2004 -- INB discovered late yesterday
that its common stock had been listed without INB's knowledge, consent or
authority on a German exchange known as the "Berlin-Bremen Stock Exchange," by
persons not yet identified, apparently for the purpose of evading the
regulations and practices of the American Stock Exchange (where INB's shares are
properly listed) and other major exchanges, and the restrictions imposed by the
NASD and SEC, which prohibit "naked shorting" practices.

"Naked shorting" occurs when a seller "sells" a stock without owning or having
borrowed it, making the seller potentially unable to deliver the stock to the
buyer. The practice of naked shorting is prohibited by other exchanges and
regulators because it facilitates abuses and manipulation, such as the sale of
fictitious shares of a company's stock in an effort to confuse, destabilize or
artificially lower the price of such company's stock.

INB and its counsel are continuing the Company's investigation, with the
cooperation of the American Stock Exchange, to identify the person or persons
who were involved in the unauthorized listing and the unusual trading practices
affecting INB's stock this week.

INB has demanded that the Berlin-Bremen Stock Exchange immediately halt trading
there of INB's stock and that the unauthorized listing be nullified. The Company
has also advised the SEC of these events and will be cooperating with the
American Stock Exchange and the regulators to investigate and halt these
practices.

INB serves the pharmaceutical, biotech and nutraceutical industries. Through
several wholly owned subsidiaries, INB develops, manufactures and distributes
more than 130 products worldwide. Its subsidiary, Paxis Pharmaceuticals, Inc.,
develops and operates a state-of-the-art GMP facility for the production and
sale of paclitaxel and related drugs. Through its biotech subsidiary, NuCycle
Therapy, Inc., INB is developing human therapeutics and preventive cancer
compounds in plants. Further information is available at
http://www.iBioPharma.com.

Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. Such
statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client. Further information on potential risk factors that could affect the
company's financial results can be found in the company's Reports filed with the
Securities and Exchange Commission.